BioAtla reports Q3 net loss $25.8M; cash $178.1M; BA3011 NSCLC shows 50% ORR in monotherapy

BioAtla, Inc.

2022-Q3 EPS reported -$2.11

Cash and cash equivalents $178.1M as of Sep 30, 2022, expected to fund operations into 2H24.
Net loss $25.8M for Q3 2022 vs $22.9M in Q3 2021; R&D expense increased to $19.8M.
BA3011 Phase 2 NSCLC: 4 PRs in monotherapy (ORR 50%) in non-squamous group; 1 CR in combination.
BA3011 UPS part 2 enrollment anticipated to start by year-end after FDA feedback; potential registrational path.
BA3071 Phase 1: first two cohorts completed without DLTs or SAEs; BA3182 IND on track by year-end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BioAtla, Inc. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

BioAtla, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022

View on SEC.gov

Browse all earnings releases →

BioAtla, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-021833

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.